Get started
Author

Andreu Vilaseca

Observed name: A Vilaseca
Institutions: Universitat Autònoma de Barcelona, Mayo Clinic, Vall d'Hebron Institut de Recerca, Mayo Clinic in Arizona, Vall d'Hebron Hospital Universitari, Centre d'Esclerosi Múltiple de Catalunya, Universitat de Barcelona
Observed institutions: Lyon 1 Université, University of Verona, Universitat Autònoma de Barcelona, Centre National de la Recherche Scientifique, Mayo Clinic, Inserm, Université de Lyon, University of Münster, Hospices Civils de Lyon, Vall d'Hebron Institut de Recerca, University Hospital Münster, Hospital Clínic de Barcelona, Mayo Clinic in Arizona, Vall d'Hebron Hospital Universitari, Consorci Institut D'Investigacions Biomediques August Pi I Sunyer, Centre d'Esclerosi Múltiple de Catalunya, Mécanismes en sciences intégratives du vivant, Universitat de Barcelona
ORCID: 0000-0001-8147-8505
Observed ORCID: 0000-0001-8147-8505
OpenAlex ID: A5014095901
Headache: A striking prodromal and persistent symptom, predictive of COVID-19 clinical evolution
2020 · Edoardo Caronna, Alejandro Ballvé, et al. · Cephalalgia · 224
PDF
Prognostic Factors for Multiple Sclerosis Symptoms in Radiologically Isolated Syndrome
2025 · Nicolás Fissolo, Sabine Schaedelin, et al. · JAMA Neurology · 26
PDF
Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis
2023 · Nicolás Fissolo, Pascal Benkert, et al. · Journal of Neurology Neurosurgery & Psychiatry · 25
PDF
Blood biomarkers for predicting disability worsening in progressive multiple sclerosis: a multinational, individual participant-level analysis
2025 · Ahmed Abdelhak, Franziska Bachhuber, et al. · Journal of Neurology Neurosurgery & Psychiatry · 20
PDF
Long‐term prognosis related to deep sedation in refractory status Epilepticus
2020 · Edoardo Caronna, Andreu Vilaseca, et al. · Acta Neurologica Scandinavica · 18
PDF
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple Sclerosis
2023 · Javier Villacieros‐Álvarez, Carmen Espejo, et al. · Annals of Neurology · 14
PDF
Contribution of Blood Biomarkers to Multiple Sclerosis Diagnosis
2025 · Manuel Comabella, Agustín Pappolla, et al. · Neurology Neuroimmunology & Neuroinflammation · 13
PDF
Algorithm to improve the diagnosis of paraneoplastic neurological syndromes associated with SOX1 antibodies
2023 · Cristina Arnaldos-Pérez, Andreu Vilaseca, et al. · Frontiers in Immunology · 13
PDF
Complement Activation Profiles Predict Clinical Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
2024 · Javier Villacieros-Álvarez, Jan D. Lunemann, et al. · Neurology Neuroimmunology & Neuroinflammation · 11
Evaluating the cost-utility of a direct transfer to angiosuite protocol within 6 h of symptom onset in suspected large vessel occlusion patients
2022 · Manuel Requena, Valeska Seguel-Ravest, et al. · Journal of Medical Economics · 8
Tumor-associated status epilepticus: A prospective cohort in a tertiary hospital
2020 · Andreu Vilaseca-Jolonch, Laura Abraira, et al. · Epilepsy & Behavior · 8
Age-Related Disability Outcomes After a First Demyelinating Event
2025 · Alvaro Cobo-Calvo, Pere Carbonell-Mirabent, et al. · Neurology · 7
Secondary organising pneumonia associated to COVID-19 infection in patients with central nervous system inflammatory demyelinating diseases treated with anti-CD20 therapies
2024 · René Carvajal, Breogán Rodríguez-Acevedo, et al. · Multiple Sclerosis Journal · 7
Neurotoxicity‐associated sinus bradycardia after chimeric antigen receptor T‐cell therapy
2022 · Eva Catalá, Gloria Iacoboni, et al. · Hematological Oncology · 6
Neurological autoimmunity in melanoma patients: a comparison between those exposed and non-exposed to immune checkpoint inhibitors
2024 · Andreu Vilaseca, Antonio Farina, et al. · Journal of Neurology · 5
The expanding spectrum of antibody-associated cerebellar ataxia: report of two new cases of anti-AP3B2 ataxia
2023 · Andreu Vilaseca, Le-Duy Do, et al. · Journal of Neurology · 5
Interleukin 6 Receptor Blockade for Relapse Prevention in Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease
2026 · Andreu Vilaseca, Philippe A. Bilodeau, et al. · JAMA Neurology · 4
Severity‐Dependent Neuroaxonal Damage Assessed by Serum Neurofilaments in ICANS Patients Undergoing CD19‐Targeted CAR T‐Cell Therapy
2025 · Andreu Vilaseca, Helena Ariño, et al. · European Journal of Neurology · 4
PDF
Uncovering alternative diagnoses in patients with clinical syndromes suggestive of multiple sclerosis: A transversal study from the prospective Barcelona CIS cohort
2025 · Andreu Vilaseca, Mar Tintoré, et al. · Multiple Sclerosis Journal · 4
Thumb-up sign: Characterization of an undescribed seizure semiologic sign
2021 · Andreu Vilaseca, Elena Fonseca, et al. · Seizure · 4
TRUE-MOGAD Score
2026 · Andreu Vilaseca, Angeliki G. Filippatou, et al. · Neurology Neuroimmunology & Neuroinflammation · 3
What Are the Proposed Mechanisms Contributing to the Manifestations of Anti-NMDAR Encephalitis?
2025 · Andreu Vilaseca, Josep O. Dalmau, et al. · Neurology · 3
Radiologically isolated syndrome: How could we accurately diagnose a subclinical period of multiple sclerosis?
2025 · Andreu Vilaseca, Angela Vidal-Jordana, et al. · Multiple Sclerosis Journal · 3
PDF
Novel Approaches to Treatment of Immune-Mediated Chronic Intestinal Pseudo-Obstruction
2025 · Andreu Vilaseca, Paula Arranz, et al. · Neurology Neuroimmunology & Neuroinflammation · 3
Clusterin deficiency is associated with a lack of response to teriflunomide in multiple sclerosis
2024 · Sunny Malhotra, Nicolas Fissolo, et al. · Clinical and Translational Medicine · 3
Works count: 53
Citation count: 398
H-index: 7
I10-index: 7
Year
Topic
Type